Skip to main content
    P

    ProQR Therapeutics BV (PRQR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.18
    -0.23 (-16.31%)

    Market Cap: $199.28M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    ProQR Therapeutics BV (PRQR) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to ProQR Therapeutics BV are Rocket Pharmaceuticals (RCKT), Korro Bio (KRRO) and Arcturus Therapeutics Holdings (ARCT). By market cap, ProQR Therapeutics BV ranks 9th of the 13 companies on this page; Prothena Corporation (PRTA) is the largest at $419.01M.

    Peer Comparison

    PRQR's revenue growth of 120.4% is above the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    ProQR Therapeutics BV (PRQR)$199.28MN/A6.1x-228.2%N/A120.4%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Korro Bio, Inc. (KRRO)$186.81MN/A175.8x0.0%-82.8%-43.1%0.00%
    Arcturus Therapeutics Holdings Inc (ARCT)$240.96MN/A7.7x-285.9%N/A6.7%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Protalix Biotherapeutics Inc (PLX)$257.17M12.1x2.9x24.3%N/A22.8%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Q32 Bio Inc (QTTB)$260.64M2.5x5.2x60.0%N/A0.0%0.00%
    NRX Pharmaceuticals Inc (NRXP)$95.58MN/A23.8x0.0%N/A0.0%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Entrada Therapeutics Inc (TRDA)$199.28MN/A53.3x0.0%-69.7%-43.9%0.00%
    Peer median$248.89M7.3x7.8x0.0%-54.0%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to ProQR Therapeutics BV, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Korro Bio, Inc. (KRRO)
    Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare...
    KRRO competitors
    Arcturus Therapeutics Holdings Inc (ARCT)
    Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases.
    ARCT competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    Protalix Biotherapeutics Inc (PLX)
    Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its...
    PLX competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Q32 Bio Inc (QTTB)
    Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune...
    QTTB competitors
    NRX Pharmaceuticals Inc (NRXP)
    NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company...
    NRXP competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors
    Entrada Therapeutics Inc (TRDA)
    Entrada Therapeutics Inc. (TRDA) is a forward-thinking biotechnology company focused on creating innovative therapies for severe diseases characterized by...
    TRDA competitors

    Frequently Asked Questions About PRQR

    Who are ProQR Therapeutics BV's main competitors?

    The companies most similar to ProQR Therapeutics BV include Rocket Pharmaceuticals (RCKT), Korro Bio (KRRO), Arcturus Therapeutics Holdings (ARCT), Prelude Therapeutics (PRLD) and Precision BioSciences (DTIL), listed from the closest match.

    Who is ProQR Therapeutics BV's biggest competitor?

    Prothena Corporation (PRTA) is the largest of the similar companies at $419.01M; Rocket Pharmaceuticals (RCKT) is the closest match by business profile, size, sector and industry.

    How does PRQR stock compare with its competitors?

    PRQR's P/S is 6.1x against a peer median of 7.8x; its net margin is -228.2% against a peer median of 0.0%.

    Which of ProQR Therapeutics BV's competitors pays a higher dividend?

    ProQR Therapeutics BV pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is ProQR Therapeutics BV bigger than its competitors?

    No. ProQR Therapeutics BV is 9th by market cap among the 13 companies on this page; the largest is Prothena Corporation (PRTA) at $419.01M.